The latest data on health complications among people living with HIV, including new findings on COVID-19 severity.
Our quick summaries of breaking conference research include new study findings on injectable long-acting cabotegravir/rilpivirine and the latest on lenacapavir, a twice-yearly injectable medication in the pipeline.
Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.
David Alain Wohl, M.D., on new findings from CROI 2021 that help us better understand the connections between sleep, diet, and quality of life among people living with HIV.
Hypertension Control Emerges as Key Concern in Examination of HIV, Aging, and Cardiovascular Disease
David Alain Wohl, M.D., talks through new data presented at CROI 2021 that further our understanding of the interplay between HIV and comorbidities we often associate with aging, particularly those related to cardiovascular disease.
David Alain Wohl, M.D., analyzes updated data regarding the intersection of HIV and COVID-19, with a particular focus on SARS-CoV-2 susceptibility and disease severity.
The incidence of anal cancer is rapidly growing in the United States, and may overtake cervical cancer within the next 10 years.
There's new research on the risk of severe COVID-19 among people living with HIV, as well as prevention and treatment options.
March 11, 2021: Anticholinergic medications and neurocognitive issues; weight gain and dolutegravir in older men; drug interaction risks on B/F/TAF; real-world efficacy of HBV-active HIV treatment.
Newly reported research includes deep dives into many health issues commonly experienced by people living with HIV, including cancer, cardiovascular disease, depression/anxiety, and metabolic disorders.